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Introduction
Stretch marks or striae distensae are tears in the dermis, above which 
the epidermis remains intact.1 Stretch marks are referred to as striae 
cutis distensae, striae gravidarum and by many other terms.1 Throughout 
this paper, the collective term striae will be used.
Striae appear as elliptical erythematous or blanched areas on the 
skin. Striae may merge to form an interwoven pattern on the affected 
area. The internal reflectance of the damaged areas often produces a 
pearlised appearance. Striae often feel softer and more pliable than the 
surrounding skin. 
Striae result from rapid expansion of the underlying tissue, e.g. during 
puberty, pregnancy or rapid weight gain.1 They may also result from 
a weakening of the dermal tissue. Striae are commonly found on 
the abdomen (especially near the umbilicus), breasts, upper arms, 
underarms, thighs, hips and buttocks.1 The prevalence of striae is high 
(up to 80% in most populations).2,3
Pregnant women are at particular risk of developing stretch marks (striae 
gravidarum) due to the combination of rapid abdominal growth and 
hormonal changes. It is estimated that 50% to 90% of women develop 
some stretch marks during pregnancy.1,3 The prevalence is higher in 
women who are already obese prior to pregnancy.3
The subject of the prevention of striae gravidarum formation is 
controversial. Many cosmetic products claim to help prevent the 
formation of stretch marks, but the ethical issues related to the conduct 
of clinical studies on pregnant women hinder objective assessment. 
Only one published randomised controlled study could be identified which 
claimed to test whether cosmetic creams prevent the development of 
stretch marks.4 This study found that only 34% of the group that used a 
daily application of a cream containing Centella asiatica extract, vitamin 
E and collagen-elastin hydrolysates developed striae, as opposed to 56% 
in the control group. In women with a history of striae during puberty, 
the active cream induced a significant absolute prevention in 89% of the 
cases, whereas all the women in the placebo group developed striae.4
Another study, with an untreated control, examined a cream which 
contained vitamin E, panthenol, hyaluronic acid, elastin and menthol. Use 
of the cream was associated with fewer stretch marks during pregnancy 
versus no treatment.5 
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Treatments that have been used to improve the appearance of existing 
stretch marks include laser treatments, laser dermabrasion, topical 
retinoids and exfoliation.6 Fractional laser resurfacing uses scattered 
pulses of light on small areas of the lesion, over several treatments. The 
pulsed laser causes micro-damage and micro-repair, hence the body 
responds to the treatment by producing new collagen and epithelium. 
The procedure improved both the texture and appearance of mature, 
white striae in skin phototypes I to IV.7
Tretinoin (0.1%) has been shown to improve the appearance of striae 
over six months when compared with a vehicle-only group.9,10 Alpha 
hydroxy acids (e.g. glycolic acid 15–20%) have also been patented 
to treat striae.11 Dermabrasion with sand and/or exfoliation with 
trichloroacetic acid (15–20%) has also been shown to be effective for 
improving the appearance of striae in all skin types.12,13 Perhaps the 
most drastic approach to the removal of striae is that of surgical removal 
of the affected areas of skin, e.g. through a “tummy tuck”.1
Many of the above modalities entail high-cost specialist treatments, often 
with the involvement of private medical practitioners. Such treatments 
are not always accessible or affordable to those who have problematic 
striae. Hence there is a huge market for over-the-counter products that 
claim to prevent or improve striae. Few studies exist to support the claims 
made by these products, and most of those that do are not published in 
peer-reviewed media.14
In South Africa, an oil-based cosmetic formulation (Bio-Oil™) has been 
produced and marketed since 1987.15 It is also marketed in 17 other 
countries. A large body of anecdotal evidence regarding product efficacy 
developed over the years. Consumers found that the product improved 
the appearance of uneven skin pigmentation, striae and scars. In early 
2005 we were approached to design and conduct objective clinical 
studies on the product to test its efficacy for those skin conditions. 
Our laboratory has been involved with the objective assessment of the 
safety and efficacy of sunscreens and cosmetic products since 1989. 
This was the first study that we conducted on striae. Striae are in fact 
scars.13,16 Consequently, scar assessment methods are appropriate in 
the study of striae. A protocol was developed in conjunction with the 
Department of Plastic and Reconstructive Surgery on the Medunsa 
Campus of the University of Limpopo.
This paper presents the findings of a 12-week study on striae, based on 
the above protocol and conducted at the Photobiology Laboratory, School 
of Pharmacy, Medunsa Campus, University of Limpopo, South Africa.
Method
Study objective
The objective of the study was to investigate the effect of 12 weeks 
of application of topically applied cosmetic oil (Bio-Oil™) on cutaneous 
striae, under randomised, controlled, observer-blinded conditions.
Sample size
Twenty healthy Caucasians with bilateral striae were included in the 
study (see below). The sample size was determined on the basis of the 








Note: as this was an exploratory study, no limit was placed on the age or 
appearance of the striae.
Exclusion criteria
•	 Breast-feeding	or	pregnant
•	 Currently	 taking	 or	 applying	 antihistamines,	 anti-inflammatories,	
corticosteroids or other medication that may affect skin reactions
•	 Suffering	from	diabetes,	circulatory	problems,	malnutrition	or	other	
conditions that may adversely affect healing processes
Randomisation and assessor blinding
The product was allocated randomly to either the right or left side of 
the panellist’s abdomen. Allocation was in such a way that 10 panellists 
applied the product to the left side and 10 to the right. The opposite side 
of the abdomen was the control site.
The assessors were blinded as to the product-treated side. The 
randomisation code was based on the study number of the panellist and 
was only broken at the end of the study, once the data analysis had been 
completed.
Study panel
Thirty-two potential panellists attended the study briefing. The panellists 
were briefed orally and given the study calendar and instructions. They 
completed a health questionnaire and informed consent form for study 
purposes at the start of the study.
Immediately after the briefing and form completion, a visual assessment 
was conducted to determine qualification for the study (to ensure that 
the proposed test sites had suitable striae). Panellists with bilateral 
abdominal striae were identified so that a half-abdomen study design 
could be adopted. 
Panellist health questionnaires and consent forms were reviewed by the 
study investigator for eligibility and completeness. Queries, omissions or 
potential problems on the forms were “flagged” for clarification at the 
baseline visit.
The 20 most suitable potential panellists were included in the study. 
Products and application
Bio-Oil™ contains a mixture of potential actives in a mineral oil, 
isopropyl myristate and cetearyl ethylhexanoate base. The actives in the 
product that are known to play a role in skin improvement include retinyl 
palmitate, tocopherol acetate and glycine soja. In addition, the properties 
of the following actives could also play a role in the improvements 
seen – Lavandula augustifolia (astringent and antiseptic), Rosmarinus 
officinalis (soothing and antiseptic), Calendula officinalis (regenerative), 
and bisabolol (anti-inflammatory).
The target application quantity was 2 mg/cm2 of product, which is a 
standard application quantity in similar skin studies. Measurement of 
the application dose was performed using a 1 ml syringe. For some 
panellists this quantity proved cosmetically unacceptable (i.e. excessive), 
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hence the panellists were allowed to apply as much as was acceptable. 
Application quantities were monitored through product weight. 
The panellists were instructed to apply the test product in the morning 
and at night, after their normal hygiene routines. They otherwise followed 
their normal cleansing and moisturising routine, except that the test 
product was used as a substitute for their normal moisturiser on the 
treated side of the abdomen. Hence, whilst the assessors were blinded 
as to the identity of the treatment sites, the panellists were aware which 
side was treated with the test product and which had undergone their 
regular moisturising routine.
The product was issued to the panellists immediately after the baseline 
assessment had been performed. The panellists were instructed how 
to apply to product and the initial application was performed under the 
supervision of a staff member not involved in the assessment. Supervised 
application was performed on the first two days of the study (Thursday 
and Friday), then on the following Monday, and then at weekly intervals 
for the first four weeks and thereafter every two weeks. 
The product was smoothed gently onto the skin and allowed to be 
absorbed, with no massage. As massage can play a role in the condition 
of skin, the panellists were instructed to apply the test product as they 
would apply their normal moisturiser, hence the role of massage was 
minimised.
Product application continued twice daily at home. An application diary 
was issued to the panellists to record the time of each application.
The product containers were weighed at the beginning and end of the 
study to monitor product use.
Assessment
Assessments were conducted by study staff with several years 
experience in skin assessment.
The assessment of the striae was carried out by means of a recognised 
scar assessment grading scale, the Patient and Observer Scar 
Assessment Scale (POSAS).16 A directed difference of relative striae 
condition was also performed. 
A detailed description of the assessments follows:
Visual evaluation – objective and blinded 
The POSAS Scar Scale is intended to be used by adding the individual 
scores from the scale’s components and obtaining a total. Any 
improvement in the scar or stria will reflect as a lower total.
The POSAS covers five parameters (vascularisation, pigmentation, 
thickness, relief, pliability), each graded on a scale of 1 to 10. The higher 
the number, the worse the stria or scar (i.e. a potential total of 50 for the 
worst possible stria). 
The change in parameters was calculated as follows:
Change in parameter (delta)
 = (score of untreated striae at time t - score of treated striae at time t) 
- (score of untreated striae at time baseline - score of treated striae at 
baseline) Equation 1
Using Equation 1, a positive value reflects an improvement in the striae 
on the treated side, over time, relative to the untreated side.
A simple directed difference was used to assess the relative condition of 
the test sites in terms of whether the right site was much worse, worse, 
the same, better or much better than the left site. 
Visual evaluation – subjective 
A subjective evaluation was performed by each panellist under the 
supervision of a study assistant, using the subjective POSAS and directed 
difference.
Data analysis
The visual data were discrete data, therefore a non-parametric statistical 
test	was	used.	The	Wilcoxon	Sign	Rank	Test	was	applied	to	the	scores.	
In addition, the number of panellists in each group who had improved, 
remained the same or worsened was calculated.
All data were recorded manually and then entered into an Excel 
spreadsheet. Proofreading was performed after data entry. After sorting 
the data according to the treatment, statistical analysis was performed. 
After the baseline assessment, the study continued for 12 weeks. The 
data for weeks 0, 4, 8 and 12 are presented below.
Ethical considerations
The study was conducted in accordance with the ‘Guidelines for good 
practice in the conduct of clinical trials in human participants in South 
Africa’.17 These guidelines are comprehensive and are based on the ICH 
Tripartite Guidelines for Good Clinical Practice (1997) and the Declaration 
of Helsinki (2000).17 
Permission to conduct the study was granted under the protocol approval 
for project MC 81/2005 of the Medunsa Campus Research and Ethics 
Committee of the University of Limpopo.
Results 
Panellist compliance
One panellist (number 7) was discharged after week 8 for protocol violation. 
This panellist had abdominal liposuction between weeks 8 and 12.
Product application quantities varied between the panellists, but were 
relatively consistent on the two sides of any given panellist. An average 
of 2.75 g of product was applied per day (or 1.375 g per application). 
Hence, if the average application area was 900 cm2, that equates to an 
application quantity of approximately 1.5 mg/cm2. 
Adverse events
There were no adverse reactions to the test product or to the panellists’ 
normal products.
Visual evaluation – objective POSAS
The objective POSAS showed no difference between the treated and 
untreated sides at week 0 (see Table I). Overall there was a relative 
improvement on the treated side, with significance from week 4 (p = 0.5).
Visual evaluation – objective directed difference
The directed difference was considered by the assessors to be the 
simplest as well as the most reliable method of comparison. The directed 
difference indicated an improvement on the treated side (see Table II). 
The improvement was statistically significant (p ≤ 0.05) at weeks 4, 8 
and	12	using	the	Wilcoxon	Sign	Rank	Test.
Original Research: The effect of a topically-applied cosmetic oil formulation on striae distensae Original Research: The effect of a topically-applied cosmetic oil formulation on striae distensae
335 Vol 51 No 4SA Fam Pract 2009
Visual evaluation – subjective POSAS
The subjective evaluation showed a perceived improvement from 
baseline that was statistically significant from four weeks onwards 
(a lower score equates to a better condition) (see Table III).
Visual evaluation – subjective directed difference
The panellists assessed the striae in overall terms by completing the 
directed difference assessment (see Table IV). These scores confirmed 
the POSAS totals in that they showed a perceived improvement on the 
treated side. 
Discussion
Both visually and instrumentally, striae are very difficult to assess.18 Their 
appearance is often pearly, and it changes depending on the angle of 
light. Striae vary considerably in size and colour, from small white pearly 
ellipses to large, contiguous pink/red dappled “zebra-stripe” lines.
A 12-week study was implemented in order to allow sufficient time for 
the effect of the product to become apparent.
The scores on the POSAS cover a relatively wide range, from 1 to 10. 
Hence it is difficult to achieve consistency on the scale from week to 
week (e.g. the same parameter scored as a 6 in one assessment week 
may be rated as a 5 at the following assessment). Using Equation 1 
allows for any drift in assessment to be eliminated, as assessment is 
narrowed down to a relative difference between the two sites.
Both the subjective assessment grades peaked at week 8. This 
phenomenon is difficult to explain, even with the loss of one panellist 
between weeks 8 and 12. 
The following graph summarises the improvements, scored on the 
POSAS scale, as perceived by the panellists (subjective) and the blinded 
assessors (objective): 
From Figure 1, it is interesting to note that the subjective assessment 
of the improvement of the treated side, relative to the untreated side, 
was considerably greater than that of the objective assessment. The 
difference could be due to one of two factors:
1. The panellist’s knowledge of which side was treated may have 
led to a positive bias. However, the panellists were predominantly 
experienced participants in clinical studies. Many were professional 
women with either postgraduate or administrative qualifications. As 
such, their opinions should be relatively objective and critical.
2. The more likely explanation is that the panellists had a completely 
different visual perspective of the striae from that of the assessors. 
The assessor was seated in front of the panellists and the panellists 
were viewed frontally, with the assessor swivelling the panellists to 
obtain a balanced view. The panellists, on the other hand, were in a 
standing position and observed their abdomens from above, hence 
their angle of observation was relatively consistent for each side. It 
may have been easier for the panellists to make a direct side-by-side 
comparison than it was for the assessor.
Table I: Objective POSAS score summary








0 20 10.9 10.8 -0.1 0.8
4 20 11.2 12.5 1.3 0.05
8 20 12.2 13.8 1.6 0.09
12 19 10.3 12.3 2 0.01
Note: See Equation 1 and Discussion for rationale for using difference between scores rather than raw scores












0 20 5 5 10 1
4 20 13 5 2 0.05
8 20 13 5 2 0.03
12 19 14 4 1 0.02
Table III: POSAS subjective score summary
Week Number in panel







0 20 25.0 24.2 -0.8 0.25
4 20 16.4 19.7 3.35 0.003
8 20 14.5 21.8 7.35 < 0.001
12 19 18.0 22.9 4.89 0.02
Table IV: Directed difference (subjective) summary









0 20 8.0 7.6 -0.4 0.07
4 20 5.7 7.4 1.7 0.02
8 20 4.0 6.8 2.8 0.0001
12 19 3.6 4.5 0.8 0.14
Figure 1: Mean improvement in scores of treated sides over untreated sides:
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The simple, directed difference measures were the most effective 
comparators.
Conclusion
Bio-Oil™ significantly improved the appearance of striae on the product-
treated side of the abdomen, as assessed by both subjective (POSAS 
and directed difference) and objective (POSAS and directed difference) 
means. The improvements were observed after four weeks of treatment 
and peaked at six to eight weeks (p = 0.05).
This study has shown that it is possible to improve the appearance 
of striae through the topical application of a relatively low-cost, non-
medicinal product.
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